Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Non-Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non-Current Assets for 6 consecutive years, with $101000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 94.28% to $101000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101000.0 through Dec 2025, down 94.28% year-over-year, with the annual reading at $101000.0 for FY2025, 94.28% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $101000.0 at TScan Therapeutics, down from $5.0 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.0 million in Q2 2022, with the low at $101000.0 in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $3.8 million, with a median of $5.0 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets soared 746.55% in 2022, then tumbled 94.28% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $5.0 million in 2021, then rose by 0.12% to $5.0 million in 2022, then tumbled by 67.3% to $1.6 million in 2023, then grew by 7.23% to $1.8 million in 2024, then crashed by 94.28% to $101000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $101000.0, $5.0 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.